sur Innovative Molecules GmbH
Innovative Molecules Advances with New EBV Antiviral Program
Innovative Molecules GmbH ("IM"), a biopharmaceutical company in Munich, has announced the expansion of its virology pipeline. The company is introducing a novel Epstein-Barr Virus (EBV) antiviral program, featuring potent polymerase inhibitors. This program is set to enter Phase 1 by 2027.
EBV is linked to serious diseases such as lymphoproliferative disorders and autoimmune conditions, yet there are few targeted antiviral treatments available. IM's new initiative highlights its commitment to addressing these unmet medical needs with specialized antiviral therapies.
Florian Vogel, CEO of Innovative Molecules, emphasized the growing importance of EBV as a therapeutic area and expressed the company's dedication to advancing innovative treatments for viral diseases. This program supports IM's strategy to develop a robust portfolio targeting high-value medical needs.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Innovative Molecules GmbH